公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2015 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions | Davidson B.; Holth A.; Hellesylt E.; Tan T.Z.; RUBY YUN-JU HUANG ; Trop? C.; Nesland J.M.; Thiery J.P. | Human Pathology | 49 | 45 | |
2012 | Early events in cell adhesion and polarity during epithelialmesenchymal transition | RUBY YUN-JU HUANG ; Guilford P.; Thiery J.P. | Journal of Cell Science | 263 | 247 | |
2017 | The EMT spectrum and therapeutic opportunities | Voon D.C.; RUBY YUN-JU HUANG ; Jackson R.A.; Thiery J.P. | Molecular Oncology | 73 | 71 | |
2013 | An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530) | RUBY YUN-JU HUANG ; Wong M.K.; Tan T.Z.; Kuay K.T.; C Ng A.H.; Chung V.Y.; Chu Y.-S.; Matsumura N.; Lai H.-C.; Lee Y.F.; Sim W.-J.; Chai C.; Pietschmann E.; Mori S.; Low J.J.H.; Choolani M.; Thiery J.P. | Cell Death and Disease | 314 | 290 | |
2016 | EMT: 2016 | Nieto M.A.; RUBY YUN-JU HUANG ; Jackson R.A.; Thiery J.P. | Cell | 3189 | 2994 | |
2014 | Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients | Tan T.Z.; Miow Q.H.; Miki Y.; Noda T.; Mori S.; RUBY YUN-JU HUANG ; Thiery J.P. | EMBO Molecular Medicine | 481 | 455 | |
2009 | Epithelial-Mesenchymal Transitions in Development and Disease | Thiery J.P.; Acloque H.; RUBY YUN-JU HUANG ; Nieto M.A. | Cell | 7952 | 7672 | |
2019 | Epithelial-to-mesenchymal transition: Lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention | Antony J.; Thiery J.P.; RUBY YUN-JU HUANG | Physical Biology | 47 | 40 | |
2013 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer | Tan T.Z.; Miow Q.H.; RUBY YUN-JU HUANG ; Wong M.K.; Ye J.; Lau J.A.; Wu M.C.; Bin Abdul Hadi L.H.; Soong R.; Choolani M.; Davidson B.; Nesland J.M.; Wang L.-Z.; Matsumura N.; Mandai M.; Konishi I.; Goh B.-C.; Chang J.T.; Thiery J.P.; Mori S. | EMBO Molecular Medicine | 159 | 151 | |
2015 | Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120) | RUBY YUN-JU HUANG ; Kuay K.T.; Tan T.Z.; Asad M.; Tang H.M.; Chun Ng A.H.; Ye J.; Chung V.Y.; Thiery J.P. | Oncotarget | 40 | 38 | |
2019 | The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma | Tan M.; Asad M.; Heong V.; Wong M.K.; Tan T.Z.; Ye J.; Kuay K.T.; Thiery J.P.; Scott C.; RUBY YUN-JU HUANG | Molecular Oncology | 17 | 14 | |
2016 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer | Antony J.; Tan T.Z.; Kelly Z.; Low J.; Choolani M.; Recchi C.; Gabra H.; Thiery J.P.; RUBY YUN-JU HUANG | Science Signaling | 89 | 91 | |
2016 | GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification | Chung V.Y.; Tan T.Z.; Tan M.; Wong M.K.; Kuay K.T.; Yang Z.; Ye J.; Muller J.; Koh C.M.; Guccione E.; Thiery J.P.; RUBY YUN-JU HUANG | Scientific Reports | 111 | 106 | |
2012 | Histotype-specific copy-number alterations in ovarian cancer. | RUBY YUN-JU HUANG ; Chen G.B.; Matsumura N.; Lai H.C.; Mori S.; Li J.; Wong M.K.; Konishi I.; Thiery J.P.; Goh L. | BMC medical genomics | 36 | 33 | |
2005 | Linking epithelial-mesenchymal transition to the well-known polarity protein par6 | Thiery J.P.; RUBY YUN-JU HUANG | Developmental Cell | 28 | 29 | |
2013 | Screening therapeutic EMT blocking agents in a three-dimensional microenvironment | Aref A.R.; RUBY YUN-JU HUANG ; Yu W.; Chua K.-N.; Sun W.; Tu T.-Y.; Bai J.; Sim W.-J.; Zervantonakis I.K.; Thiery J.P.; Kamm R.D. | Integrative Biology (United Kingdom) | 139 | 126 | |
2019 | SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition | Sundararajan V.; Tan M.; Tan T.Z.; Ye J.; Thiery J.P.; RUBY YUN-JU HUANG | Scientific Reports | 30 | 29 | |
2011 | Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept | Chua K.-N.; Poon K.L.; Lim J.; Sim W.-J.; RUBY YUN-JU HUANG ; Thiery J.P. | Advanced Drug Delivery Reviews | 39 | 37 | |
2012 | Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer | RUBY YUN-JU HUANG ; Chung V.Y.; Thiery J.P. | Current Drug Targets | 66 | 64 | |
2010 | Transitions between epithelial and mesenchymal states in microfluidic platform: Acquisition of malignant and stem cell traits | Aref A.R.; RUBY YUN-JU HUANG ; Kang W.; Jing S.W.; Thiery J.P.; Kamm R.D. | Nanotechnology 2010: Electronics, Devices, Fabrication, MEMS, Fluidics and Computational - Technical Proceedings of the 2010 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2010 | 0 |